Resmetirom

Resmetirom
Clinical data
Trade names	Rezdiffra
Other names	MGL-3196
AHFS/Drugs.com	Monograph
License data	US DailyMed: Resmetirom;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile;
CAS Number	920509-32-6;
PubChem CID	15981237;
DrugBank	DB12914;
UNII	RE0V0T1ES0;
KEGG	D11602;
ChEMBL	ChEMBL3261331;
CompTox Dashboard (EPA)	DTXSID601352610 ;
Chemical and physical data
Formula	C17H12Cl2N6O4
Molar mass	435.22 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl;
	InChI InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28); Key:FDBYIYFVSAHJLY-UHFFFAOYSA-N;

Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. It is a thyroid hormone receptor beta (NR1A2) agonist.

The most common side effects include diarrhea and nausea.

Resmetirom was approved for medical use in the United States in March 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.